References
Turnidge J, Grayson ML. Drugs 45: 353–366, 1993
Brogden RN, Peters DH. Drugs 47: 823–854, 1994
Sahai J, et al. Antimicrob Agents Chemother 34: 765–769, 1990
Davey PG, Williams AH. J Antimicrob Chemother 27 (Suppl B): 69–73, 1991
Levine JF. Med Clin North Am 71: 1135–1145, 1987
Gilbert DN, et al. Antimicrob Agents Chemother 35: 79–87, 1991
Wilson APR, et al. Int J Antimicrob Agents 4 (Suppl 1): 1–30, 1994
Kacet N, et al. Pediatr Infect Dis J 12: S10–S13, 1993
Martino P, et al. Clin Infect Dis 15: 290–294, 1992
Nováková I, et al. Antimicrob Agents Chemother 35: 672–678, 1991
Van der Auwera P, et al. Antimicrob Agents Chemother 35: 451–457, 1991
Rolston K, et al. J Infect Dis 169: 350–355, 1994
Schaison GS, Decroly FC. J Antimicrob Chemother 27 (Suppl B): 61–67, 1991
Dagan R, et al. Pediatr Infect Dis J12: S17–S20, 1993
Edelstein HE, et al. Ann Pharmacother 25: 914–918, 1991
Lim SH, et al. J Antimicrob Chemother 28: 109–116, 1991
Menichetti F, et al. Satellite Symposium to the 18th International Congress of Chemotherapy, Stockholm, Sweden, 1993
Rybak MJ. Hosp Formul 28: 28–32, 1993
Craven PC. Hosp Formul 28: 41–45, 1993
Crane VS, et al. Hosp Formul 27: 1199–1210, 1992
Rights and permissions
About this article
Cite this article
Teicoplanin: a better-tolerated alternative to vancomycin in serious Gram-positive infections. Drugs Ther. Perspect 4, 1–4 (1994). https://doi.org/10.2165/00042310-199404060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199404060-00001